Objective

IndicatorData components and sourceLikely report date/Implementation Plan
HCV 1
To reduce the incidence of hepatitis C
1.Annual incidence of hepatitis C in people who inject drugsNumerator: Number of people who inject drugs who participate in the Australian Needle and Syringe Program Survey who test anti-HCV negative and HCV-RNA positive
Denominator: Number of people who inject drugs who participate in the Australian Needle and Syringe Program Survey
Currently not available
Blood samples are currently collected through Australian Needle and Syringe Program survey and are tested for anti-HCV but not HCV-RNA. BBVSS to consider options for HCV-RNA testing, by end 2011.
2.Annual incidence of hepatitis C in people who inject drugsNumerator: Number of people who inject drugs who participate in 1. NSW Hepatitis C Incidence and Transmission – community Study (HITS-c) and 2. Victoria Networks Study who test HCV-RNA positive who were HCV-RNA negative in the previous 12 months
Denominator: Number of people who inject drugs who participate in 1. NSW Hepatitis C Incidence and Transmission – community Study (HITS-c) and 2. Victorian Networks Study who were HCV-RNA negative in the previous 12 months
2011
HCV 2
To increase access to new injecting equipment through needle and syringe programs
1.Rate of needles and syringes distributed in the previous calendar yearNumerator: Number of needles and syringes distributed by public and pharmacy needle and syringe program sectors reported by state and territory health departments
Denominator: Number of people who inject drugs, estimated by modelling
Currently not available
Numerator: Kirby Institute to recommend standardisation, collection and reporting protocols for routine reporting of jurisdictional Needle and Syringe Program distribution data, by end 2011.

Denominator: Kirby Institute to recommend options for estimating number of people who inject drugs in each jurisdiction, by end 2011.
2.Proportion of all injections by people who inject drugs in which a new needle and syringe was used in the previous calendar yearNumerator: Number of syringes obtained by people who inject drugs from all sources in the last month minus those given away or sold, obtained from Australian Needle and Syringe Program Survey
Denominator: Number of monthly injections per person who injects drugs, obtained from Australian Needle and Syringe Program Survey
Currently not available
Kirby Institute to recommend whether to include relevant question module in Australian Needle and Syringe Program Survey every second year, starting 2012.
3. Proportion of people who inject drugs reporting re-using another person’s used needle and syringe in the previous monthNumerator: Number of Australian Needle and Syringe Program Survey participants who inject drugs reporting re-use of another person’s used needle in month preceding survey

Denominator: Number of people who inject drugs who participate in the Australian Needle and Syringe Program Survey
2011
See HIV 2.2
HCV 3
To reduce the burden of disease attributed to chronic hepatitis C
1.Estimated number of people with hepatitis C infection by stage of liver disease Estimated number of people living with hepatitis C infection with each stage of liver disease, obtained from modelling based on estimates of HCV incidence and prevalence, rates of viral clearance, rates of progressive cirrhosis in chronically infected people, anti-HCV treatment rates and treatment response2012
Kirby Institute Hepatitis C Projections Working Group to oversee updating of estimates for 2012 report onward.
2.Self-reported health status by people with hepatitis CTo be determinedCurrently not available
National Centre for HIV Social Research to provide advice to BBVSS on options to develop and validate measures of self-report health status in people with hepatitis C, and opportunities for including self-reported health status in relevant surveys and, by end 2011. See also HCV 5.
HCV 4
To increase access to clinical care for people with chronic hepatitis C
Proportion of people with chronic hepatitis C dispensed drugs for their infection through the Highly Specialised Drugs Program in the previous calendar year.

Numerator: Number of individuals dispensed medications for hepatitis C infection through Highly Specialised Drugs Program

Denominator: Estimated number of people living with hepatitis C infection, obtained from modelling based on estimates of HCV incidence and prevalence, rates of viral clearance, rates of progressive cirrhosis in chronically infected people, anti-HCV treatment rates and treatment response.
2011 (numerator data only; denominator data currently not available)
Numerator: See HBV 3.3.
Denominator: See HCV 3.1
HCV 5
To reduce hepatitis C-related stigma and discrimination in healthcare settings
Proportion of people with hepatitis C who report discrimination in healthcare settingsTo be determinedCurrently not available
National Centre for HIV Social Research to advise on options to develop and validate measures of self-reported discrimination in people with hepatitis C, and opportunities for including self-reported discrimination in relevant surveys and, by end 2011. See also HCV 3.2.